ARQT Stock Analysis: Buy, Sell, or Hold?
ARQT - Arcutis Biotherapeutics, Inc. Common Stock
$21.01
0.54 (2.64%)
▲
5d:
-2.6%
30d:
-11.54%
90d:
-17.33%
HOLD
MODERATE Confidence
Analysis Updated: May 21, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Get Alerted When ARQT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called ARQT this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ARQT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ARQT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$56.26
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$34.94
39.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ARQT is currently trading at $21.01, which is considered oversold relative to its 30-day fair value range of $21.09 to $24.17. From a valuation perspective, the stock is trading at a discount (Forward PE: 17.7) compared to its historical average (39.5). Remarkably, the market is currently pricing in an annual earnings decline of 23.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ARQT is in a strong downtrend. Immediate support is located at $19.30, while resistance sits at $22.45.
Market Sentiment: ARQT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $34.62 (+69.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ARQT is in a strong downtrend. Immediate support is located at $19.30, while resistance sits at $22.45.
Market Sentiment: ARQT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $34.62 (+69.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$21.09 -
$24.17
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding ARQT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 69.1% below Wall St target ($34.62)
Trading Range Analysis
30-Day Trading Range
$21.09 -
$24.17
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$19.30
Resistance Level
$22.45
Current Trend
Strong Downtrend
Technical data as of
May 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.71
Wall Street Target
$34.63
(+69.1%)
Revenue Growth (YoY)
60.1%
Profit Margin
-0.6%
Valuation Discount vs History
-23.5% cheaper
PE vs Historical
17.7 vs 39.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-23.5%
(market-implied from PE analysis)
1-Year Target
$18.42
(-10%)
2-Year Target
$16.58
(-19%)
3-Year Target
$14.92
(-27%)
3-Yr Target (if PE normalizes)
(PE: 18→40)
$33.28
(+63%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.1, Growth: 371.7%)
$86.01
(+320%)
Base:
(SPY PE: 17.7, Growth: 371.7%)
$69.09
(+238%)
Bear:
(PE: 15.1, Growth: 371.7%)
$58.72
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 17.7 to 39.5
Stabilization Target:
$45.65
(+123.0%)
PE Expansion Potential:
+123.0%
Share & Embed Analysis
Last updated: May 21, 2026 4:19 PM ET
Data refreshes hourly during market hours. Next update: 5:19 PM
Data refreshes hourly during market hours. Next update: 5:19 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARQT showing a specific setup today?
Insider Activity (6 Months)
1
Buys
19
Sells
Net
INSIDERS SELLING
Recent Transactions
Howard G Welgus
SELL
10000 shares
2026-04-01
Gilbert Ray Cisneros, Jr.
BUY
2026-03-03
Larry Todd Edwards
SELL
3687 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 60 HOLD |
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 50 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 58 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 59 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 53 HOLD |
Advanced ARQT Option Strategies
Professional options setups generated by AI based on today's ARQT price and gamma walls.
